Gonadotropin-releasing hormone agonist and add-back therapy: What do the data show?

Current Opinion in Obstetrics and Gynecology

Volumn 22, Issue 4, 2010, Pages 283-288

  Surrey, Eric S ^a  

^a National Foundation for Fertility Research   (United States)

Author keywords

add back; chronic pelvic pain; endometriosis; GnRH agonist; progestin

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; DESOGESTREL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETIDRONIC ACID; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; MEDROGESTRONE; MEDROXYPROGESTERONE ACETATE; NAFARELIN; NORETHISTERONE; NORETHISTERONE ACETATE; PAMIDRONIC ACID; PLACEBO; PROGESTIN PROMEGESTONE; TIBOLONE; UNCLASSIFIED DRUG; GONADORELIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADOLESCENCE; ARTHRALGIA; BONE DENSITY; BREAKTHROUGH BLEEDING; CHOLESTEROL BLOOD LEVEL; CHRONIC PAIN; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIOSIS; FEMALE INFERTILITY; GYNECOLOGIC DISEASE; HUMAN; LIBIDO DISORDER; LOW DRUG DOSE; MOOD DISORDER; OSTEOLYSIS; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VASOMOTOR DISORDER; ADOLESCENT; ADULT; AGONISTS; CHEMICALLY INDUCED; FEMALE; HORMONE SUBSTITUTION; OSTEOPOROSIS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ENDOMETRIOSIS; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; PROGESTINS; YOUNG ADULT;

EID: 77954660423     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32833b35a7     Document Type: Review

References (34)

1. Wheeler J. Epidemiology of endometriosis-associated infertility. J Reprod Med 1989; 34:41-46.
2. Matorras R, Cobos P. Epidemiology of endometriosis. In: Garcia-Velasco J, Rizk B, editors. Endometriosis: current management and future trends. New Delhi: Jaypee; 2010. pp. 10-16.
3. Laufer M, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199-202.
4. Osteen K, Bruner K, Sharpe-Timms K. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 1996; 15:301-308.
5. Noble L, Simpson E, Johns A, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996; 81:174-179.
6. Bulun S, Cheng Y-H, Pavone M, et al. Estrogen receptor-b, estrogen receptor a, and progesterone resistance in endometriosis. Semin Reprod Med 2010; 28:36-43.
7. Batzer F. GnRH analogs: option for endometriosis-associated pain treatment. J Min Inv Gynecol 2006; 13:539-545.
8. Olive D. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med 2008; 359:1136-1142.
9. BilotasM, Baranäo R, Buquet R, et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and Fas L proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Hum Reprod 2007; 22:644-653.
10. Ferrero S, Gillott D, Remorgida V, et al. GnRH analogue remarkably downregulates inflammatory proteins in peritoneal fluid proteome of women with endometriosis. J Reprod Med 2009; 54:223-231.
11. Levine D, Kaufman L, Cuenca V, Badawy S. Cell growth effects of leuprolide on cultured endometrioma cells. J Reprod Med 2007; 52: 581-584.
12. Sharpe-Timms K, Keisler L, McIntosh E, Keisler D. Tissue inhibition of metalloproteinase-1 concentrations are attenuated in peritoneal fluid and sera of women with endometriosis and restored in sera by gonadotropinreleasing hormone agonist therapy. Fertil Steril 1998; 69:1128-1134.
13. Meresman G, Bilotas M, Lombardi E, et al. Effect of GnRH analogues on apoptosis and release of interleukin-1b and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2005; 18:1767-1771.
14. Surrey E. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Fertil Steril 1999; 71:420-424.
15. Hornstein M, Surrey E, Weisberg G, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 1998; 91:16-24.
16. Surrey E, Hornstein M. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long term follow-up. Obstet Gynecol 2002; 99:709-719.
17. Cedars M, Lu J, Meldrum D, Judd H. Treatment of endometriosis with a longacting goandotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990; 75:641-645.
18. Makarainen L, Ronnberg L, Kaupilla A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropinreleasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 1996; 65:29-34.
19. Surrey E, Gambone J, Lu J, Judd H. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53:620-626. (Pubitemid 20143041)
20. Bergqvist A, Jacobson J, Harris S, et al. A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecol Endocrinol 1997; 11:187-194.
21. Taskin O, Yalcinoglu A, Kucuk S, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67:40-45.
22. Barbieri R. Endometriosis and the estrogen threshold theory: relation to surgical and medical treatment. J Reprod Med 1998; 43:287-292.
23. Edmonds D, Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis? Br JObstetGynaecol1994;101 (Suppl 10): 24-26.
24. Moghissi K, Schlaff W, Olive D, et al. Goserelin acetate (Zoladex) with or without hormone replacement for the treatment of endometriosis. Fertil Steril 1998; 69:1056-1062.
25. Franke H, van de Weijer P, Pennings T, van der Mooren M. Gonadotropinreleasing hormone agonist plus 'add-back' hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 2000; 74:534-539.
26. Freundl G, Godtke K, Gnoth C, et al. Steroidal 'add-back' therapy in patients treated with GnRH agonists. Gynecol Obstet Invest 1998; 45 (Suppl 1): 22-30.
27. Surrey E, Voigt B, Fournet N, Judd H. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone 'add-back' therapy. Fertil Steril 1995; 63:747-755.
28. Fernandez H, Lucas C, Hédon B, et al. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod 2004; 19:1465-1471.
29. Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis associated pain. Fertil Steril 2004; 82:1303-1308.
30. Fuldeore M, Marx S, Chwalisz K, et al. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin 2010; 76:729-736.
31. Laufer M. Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 2008; 66 (Suppl 1):19-27.
32. Di Vasta A, Laufer M, Gordon C. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol 2007; 20:293-297.
33. Kiesl L, Schweppe K-W, Sillam M, Siebzehnrübl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 1996; 103 (Suppl 14):15-17.
34. Al-Azemi M, Jones G, Sirkeci F, et al. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. Br J Obstet Gynaecol 2009; 116:1646-1656.